WHO member states kicked off one more attempt at finalising the missing piece of the pandemic treaty on Monday, with the Ebola outbreak injecting a fresh sense of urgency.

Wealthy countries and developing nations are at loggerheads in talks at the World Health Organization’s headquarters over how the pandemic agreement, adopted last year, will work in practice.

Though the treaty was agreed in May 2025, how its key mechanism would operate was left out to get the deal over the line.

The agreement’s Pathogen Access and Benefit-Sharing (PABS) system deals with sharing access to pathogens with pandemic potential, then sharing benefits derived from them such as vaccines, tests and treatments.

It was meant to be finalised long before May 2026, but progress has been agonisingly slow.

Negotiations have often gone late into the night, producing miniscule advances and leaving diplomats drained — especially those from small countries with only a handful of staff in Geneva covering every branch of the UN.

This two-week session until July 17 is the seventh such round of talks.

WHO chief Tedros Adhanom Ghebreyesus urged countries to grasp the nettle.

“You could have given up,” saying “that we will never agree”, Tedros told countries as the talks opened.

However, “you said we don’t agree yet, but we believe we can.”

“Please keep the destination in sight,” urged the UN health agency’s director-general.

“A future in which pathogen samples and information move quickly, without needless delay; and in which the benefits that come from them reach the people who need them most, fairly and in time.”

‘Danger can emerge from anywhere’

The Ebola outbreak in the Democratic Republic of Congo, declared in mid-May, is a reminder that the next pandemic threat could spring up from anywhere, Tedros said.

There have been 1,528 confirmed cases, including 492 confirmed deaths, in DR Congo, and the outbreak has spilled over into neighbouring Uganda.

“Ebola may not be the next pandemic. But it is a reminder, a painful one, that the threat never truly goes away,” said Tedros.

The deadly hantavirus outbreak on a cruise ship, declared over on Thursday, also shows “danger can emerge from anywhere, at any time, in ways we don’t always expect”.

The outbreak on the MV Hondius, sailing the Atlantic Ocean, led to a global health alert affecting 33 countries and territories.

“Every month that this annex remains unfinished is a month the world stays less prepared than it could be. It is people — real people, real families — left less safe than they deserve to be,” said Tedros.

The pandemic agreement was struck after more than three years of negotiations sparked by the shock of Covid-19.

The accord aims to prevent a repeat of the disjointed international response that surrounded the coronavirus crisis, by improving global coordination, surveillance and access to vaccines.

Only once the PABS annex is complete will countries be able to start ratifying the treaty.

Source: https://english.ahram.org.eg/UI/Front/Inner.aspx?NewsContentID=572309

Fight the Censorship Join the Hopegirl Mailing List and get my free AudioBook: The QEG Chronicles Free Energy Full Disclosure: https://bit.ly/HGQEGBook

HopeGirl Youtube: https://www.youtube.com/@hopegirlblog
HopeGirl Telegram Channel Chat and Groups: https://t.me/Hopegirl587 
Get Our Free EMF Survival Guide : https://bit.ly/FTWEMF
10 Percent Off our EMF Protection Products with this Link: https://www.ftwproject.com/ref/tenoff

The post Jolted by Ebola, countries try again to finish pandemic treaty appeared first on HopeGirl Blog.

Ebola is rare and unlikely to cause a pandemic. Despite this, the World Health Organisation has declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a public health emergency of international concern (“PHEIC”).

The true cause of Ebola outbreaks is unlikely to be wild animals, as claimed by the WHO, but rather gain-of-function research being conducted in laboratories across the globe, including in the regions where these outbreaks occur.

Declaring an outbreak as a PHEIC is an opportunity for pharmaceutical companies and researchers to profit from the development of vaccines and therapeutics.

Ebola: Public Health Crisis or Criminal Enterprise?

By New Zealand Doctors Speaking Out with Science (“NZDSOS”), 29 May 2025

Table of Contents

1. Introduction
2. What is Ebola?
3. Ebola History and Epidemiology
4. How is Ebolavirus Disease Diagnosed?
5. How is Ebolavirus Treated?
6. What Causes an Ebola Outbreak?
7. Pandemics Profit Pandemic Prophets
8. Conclusion

Introduction

Hot on the tail of hantavirus histrionics, the World Health Organisation (“WHO”) declared on 17 May 2026 that an epidemic of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda is a public health emergency of international concern (aka a PHEIC).

As the 79th session of the World Health Assembly wrapped up last week, it is easy to see the priorities of WHO in these four brief headlines from the front page of their website. Without frightening diseases, how will the pandemic agreement be reached, or the global health architecture be built?

What is Ebola?

Ebolavirus belongs to the Filovirus family, named for their thread-like appearance under electron microscopy (“filum” is Latin for “thread”). There are six known subtypes, four of which are associated with human disease. It is claimed that wild animals are the source of initial infection, followed by human-to-human transmission via direct contact with the blood and body fluids of an infected person.

Ebolavirus disease (“EVD”) presents initially as an influenza-like illness, followed by vomiting, diarrhoea, skin rash, impaired kidney and liver function, and impaired neurological status with confusion, irritability and aggression. Internal and external bleeding from any organs can occur, but is less frequent than the aforementioned symptoms.

Ebola History and Epidemiology

According to Laurie Garret in ‘The Coming Plague’ (1994), the first case of EVD was detected in August 1976 in a school teacher from Yambuku in Northern Zaire (now the Democratic Republic of Congo or DRC), near the Ebola river. The subsequent outbreak in this region occurred simultaneously with an outbreak in Southern Sudan. A public health investigation dispatched virologists and epidemiologists from their laboratories in Europe and North America into the deep heart of the African continent.

Tissue specimens were sent to laboratories in Europe and the USA to determine a causative agent. On 10 October 1976, scientists at the Centres for Disease Control and Prevention’s maximum-security laboratory in Atlanta officially informed the World Health Organisation that the causative agent was “a virus that resembles Marburg.“

Serial passage experimentation began almost immediately, “passing Ebola samples from one guinea pig to another to see if the virulence of the virus was diminished as it went through successive generations of animals.” A contamination incident in a UK laboratory resulted in at least one researcher becoming unwell and being successfully treated with plasma from a recovered African patient.

Since that time, there have been more than 25 EVD outbreaks involving the loss of 15,000 lives across a fifty-year timespan. Seventeen of these outbreaks have occurred in the DRC, also currently affected, which was also ground zero for Mpox (formerly known as monkeypox) in 2022. Most outbreaks have been confined to rural areas in five of Africa’s 54 countries: Sudan, DRC, Gabon, the Republic of Congo and Uganda.

The Bundibugyo subtype, responsible for the current public health emergency of international concern (“PHEIC”), was first identified in the Bundibugyo region of Uganda during an outbreak in 2007. A second Bundibugyo outbreak followed in the DRC in 2012, and today’s outbreak is the third involving this subtype.

For context, in the year 2024 alone, tuberculosis killed 1.23 million people and malaria killed 610,000 people. The African continent bears the highest burden of these diseases.

How is Ebolavirus Disease Diagnosed?

Clinical symptoms of EVD are difficult to distinguish from other infectious diseases such as malaria, typhoid fever and meningitis, which are endemic to the geographic region where EVD outbreaks sporadically occur. A range of diagnostic tests has been developed to confirm the presence of Ebolavirus.

The World Health Organisation recommends nucleic acid amplification testing (“NAAT”), of which polymerase chain reaction (“PCR”) is a frequently used technique, with genome sequencing to categorise the subtype. As of 22 May 2026, the Africa Centres for Disease Control and Prevention recommends PCR testing as below.

It is important to always remember the flaws and potential corruptibility in using PCR to diagnose disease, especially when symptoms may be caused by other, more common endemic diseases. Pseudoepidemics can occur in world-class facilities. A much higher risk exists in locations with limited resources and an abundance of sickness and premature death, especially if panic and fear have been galvanised, as we are witnessing today.

How is Ebolavirus Treated?

Early treatment ensures the best possible outcomes, as with any disease. Hydration management via oral or intravenous fluids is important. Monoclonal antibodies may be useful, depending on the subtype. There has been no research into the benefits of repurposed drugs in Ebola treatment but it seems likely that ivermectin and hydroxychloroquine, effective in other RNA virus infections, may be useful. Instead, the World Health Organisation and its sponsors are focused on finding new countermeasures (vaccines and therapeutics) to patent and sell at a profit.

What Causes an Ebola Outbreak?

According to the World Health Organisation, Ebolavirus is “transmitted to people from wild animals (such as fruit bats, porcupines and non-human primates).” Contact with the blood or body fluids of an infected person can then result in human-to-human transmission.

What this assertion ignores, however, is the Ebolavirus gain-of-function research occurring in laboratories across the globe, including across the region where these sporadic outbreaks occur. Such research is always claimed to be for reasons that are in the public’s best interest, for example, to develop countermeasures such as vaccines and therapeutics. Yet the work is shrouded in secrecy.

In a 2015 report on Ebola research at the Commonwealth Scientific and Industrial Research Organisation (“CSIRO”) in Geelong, Victoria, SBS held firmly to the claim that Ebola outbreaks are due to crossover from wild animals. Nevertheless, the same report stated that: “If any of these viruses were to make it out of the lab, it could have deadly consequences.“

In the USA, Rocky Mountain Laboratories in Montana is known to be infecting animals with a range of pandemic-potential viruses, including Ebola. The research involves torturing animals known as maximum-pain virus experiments.

The White Coat Waste Project has exposed a number of biosafety breaches in these laboratories which pose a threat to public health, setting aside the welfare of the animals for a moment.

Late last year, during experimentation with Crimean-Congo Haemorrhagic Fever, a staffer was “bitten by an infected monkey (macaque) that was being tortured (infected and sickened with no pain mitigation).” Earlier this year, Vincent Munster, a virologist at the Rocky Mountain Laboratories, was caught smuggling dangerous pathogens, including Clade 1B Mpox, from the DRC into the USA.

The US Army Medical Research Institute of Infectious Diseases (“USAMRIID”) at Fort Detrick, 50 miles from Washington DC, employs 900 researchers to experiment with “biological threats” including Ebola. USAMRIID developed Ervebo, the first Ebola vaccine, licensed in 2019.

On the African continent, where regulation has even less oversight, a number of laboratories are likely to be involved in gain-of-function research. The proximity of these laboratories to the “ground zero” of outbreaks gives pause for thought to even the least conspiracy-minded amongst us.

In our August 2024 Mpox article, we raised suspicions about the Rodolphe Mérieux Foundation’s high-security facility in Goma, DRC.  Situated in North Kivu Province, eastern DRC, Goma lies on the border with South Kivu Province, around 500km from Kamituga, where Clade IB of Mpox was first detected. That alone is a coincidence deserving of raised eyebrows. Even more suspicious is the fact that ground zero of the current Ebola outbreak lies a very similar distance from Goma, in the opposite direction.

The first case of Nipah virus, in a much-publicised outbreak earlier this year, was detected in Kolkata, the provincial capital of West Bengal in India. This is approximately 500km from another Rodolphe Mérieux Laboratory at the Bangladesh Institute of Tropical and Infectious Diseases in Chattogram (Chittagong).

Mérieux Laboratories are partnered with local reference laboratories, academic, university and hospital research institutes across low-income nations in what they named the GABRIEL Network – an acronym for “global approach to biology research, infectious diseases and epidemics in low-income countries.” The stated aim is “to build capacity and improve laboratory-based surveillance of diseases with a major impact on public health in developing countries.” Sponsors include the Bill & Melinda Gates Foundation, among others.

Could this potentially be a front for more nefarious activities? As we documented in March 2026, the Coalition for Epidemic Preparedness Innovations (“CEPI”) was established in 2017 at the World Economic Forum in Davos and received a significant amount of early funding from the Bill & Melinda Gates Foundation. It is a direct institutional descendant of the pandemic preparedness funding architecture documented in the Epstein files.

[Related: Epstein Files Mention Pandemic Simulations Linked to Bill Gates, Tempo, 4 February 2026 and The Epstein Files Illuminate a 20-Year Architecture Behind Pandemics as a Business Model – With Bill Gates at the Centre of the Network, Sayer Ji, 2 February 2026]

In January 2026, CEPI paid $26.7 million to Moderna and the University of Oxford to develop mRNA and viral vector injections that target the Bundibugyo strain. This business decision came just four months before the outbreak began. What are the chances that this timing was coincidental?

One of the many projects listed at the Uganda Virus Research Institute in Entebbe, receiving philanthropic donations from Wellcome Trust and the Bill & Melinda Gates Foundation, is “CEPI: Advancing Global Vaccine Preparedness.” The project claims to conduct “rigorous, standardised testing of vaccine candidates for priority diseases, including Ebola, Marburg, Lassa, Nipah, Rift Valley Fever, SARS-CoV-2, Mpox and unidentified emerging threats,” and to develop and optimise “critical assays for the detection of immune responses against Ebola and Marburg viruses.”

Is it possible that this laboratory is working with live Ebolaviruses? Could that explain the laboratory’s uncanny distance from Bundibugyo, a town and district in western Uganda where the current outbreak strain was first identified in 2007? Bundibugyo and Bunia are about 270km apart, and recent reports claim that the outbreak is spreading in Uganda. Do the Rodolphe Merieux Laboratory in Goma and the Uganda Virus Research Institute in Entebbe have anything to do with these outbreaks that are being blamed on spread following contact with wild animals?

Pandemics Profit Pandemic Prophets

University of North Carolina (“UNC”) Chapel Hill virologist Ralph Baric, considered a pioneer of gain-of-function research, recently had his research grants stopped and was placed on leave by UNC Chapel Hill. This seems to be due to implications of his coronavirus research at the Wuhan Institute of Virology.

In 2018, Baric gave a 40-minute presentation, available on YouTube, in which he prophesied that a pandemic was looming. Many of the people who profit from claims of a pandemic have made similar prophesies. In the clip below, Baric boasted to the audience about the profits that can come from a pandemic. These are consistent with similar boasting from Belgium’s 2009 Swine Flu commissioner at Chatham House in 2019.

https://www.youtube.com/embed/UuERPvBFfco?start=1945&feature=oembedUNC Public Health: Imagining the Next Flu Pandemic – and Preventing it!, 29 May 2018 (38 mins)

[If the video above is removed from YouTube, you can watch it on Rumble HERE. An auto transcription of the first 30 mins of the video is attached below.]

Ralph Baric UN Public Health 2018Download

In the current Ebola outbreak, public funds have been committed so far to the tune of US$645 million. With a grand total of 101 confirmed cases, this amounts to $6.3 million per confirmed case. In a nation where the average annual income is US$670, this is obscene and irrelevant to the health or any other needs of the population.

On 24 May 2026, Tedros Ghebreyesus released a video clip on social media announcing the activation of complex networks focused on developing and trialling countermeasures, therapeutics and candidate vaccines. We have written about this Ponzi scheme previously, in which taxpayers cover all risk, the industry receives all benefits and population health remains a very firm loser. The model is explained in this one easy infographic from Dr. David Bell.

Conclusion

A number of viral haemorrhagic fevers are touted as candidates for the repeatedly foretold “next pandemic.“ None evokes more fear than Ebola. This makes it highly marketable despite the fact that it does not transmit easily and outbreaks always ultimately abate naturally.

Ebola is a tiny blip on the landscape of infectious disease threats. Diagnostic practices need to be evaluated closely to ensure that outbreaks are not pseudo-epidemics. Ebola elicits sensation because of the exotic and adventurous nature of Ebola-related research for scientists paid to investigate outbreaks in intrepid locations and to develop “innovative” prevention and treatment technologies. This alone creates a potential conflict of interest in truth-seeking.

Despite the hype, Ebola is very unlikely to be the cause of a pandemic, and so it is unclear as to why someone like Robert Redfield, former CDC Director, would make a claim that “I suspect this is going to become a very significant pandemic.” His financial and other conflicts of interest should be examined closely.

It seems likely that profits, not wild animals, are driving the consecutive public health emergencies of international concern (“PHEICs”) declared back-to-back by WHO, including Ebola. It is clear that exorbitant amounts of money are being injected into Ebola research by the nefarious characters involved in building a global pandemic architecture.

Gain-of-function posing as vaccine research for rare diseases which pose little threat to most people, must be stopped. Disease diagnosis must be held to a standard that respects the diagnostic process as one requiring skilled clinicians referring to a range of appropriate laboratory tests, when necessary, not merely a narrow focus on one single test with potential for misdiagnosis. Fear as a method of control must be removed from all public health strategies and replaced once more with common sense and ethics. Finally, an investigation into the criminality of those attempting to overthrow medicine and public health is required, and appropriate consequences instituted.

Of note: The Focal Points website of the McCullough Foundation is publishing much original investigation into the fear-mongering and flourishing pipeline of these scary viruses and their profiteers. 

Source: https://theexposenews.com/2026/06/10/ebola-profits-not-wild-animals-are-driving-who/

Fight the Censorship Join the Hopegirl Mailing List and get my free AudioBook: The QEG Chronicles Free Energy Full Disclosure: https://bit.ly/HGQEGBook

HopeGirl Youtube: https://www.youtube.com/@hopegirlblog
HopeGirl Telegram Channel Chat and Groups: https://t.me/Hopegirl587 
Get Our Free EMF Survival Guide : https://bit.ly/FTWEMF
10 Percent Off our EMF Protection Products with this Link: https://www.ftwproject.com/ref/tenoff

The post Ebola: Profits, not wild animals, are driving WHO to declare public health emergencies appeared first on HopeGirl Blog.

At the end of last month, Dr. Leonard G. Horowitz submitted a policy review to the CDC for publishing.  In his brief review, he pointed out that previous Ebola outbreaks were linked to viruses taken from monkey tissues and added to human vaccines.

HIV/AIDS is also linked to the contents of vaccines.

Investigations should be conducted to ensure that dual-use laboratory research is not the real origin of the current Ebola outbreak, he says.

The lady in the video below says that she is reporting from the Democratic Republic of Congo (“DRC”).  The video doesn’t state where in the DRC she is or the date the video was made.  She has been in the DRC for a couple of months, she says, and “there is no Ebola here.”

It seems that the World Health Organisation (“WHO”) has a crystal ball because, as the tweet below notes, four weeks before the Ebola outbreak was announced, WHO approved an Ebola vaccine.

Is it any wonder that people are not able to take WHO chief Dr. Tedros Adhanom Ghebreyesus’ trip to the DRC seriously?  His presence in the DRC is reminiscent of a criminal returning to the scene of the crime,  like an arsonist who starts the fire and then joins the crowd feigning “what’s happening, what’s going on” while secretly gloating over his handiwork.

In the following, Dr. Leonard G. Horowitz highlights that previous Ebola outbreaks and HIV/AIDS have followed a pattern, and that there are indications that the current Ebola outbreak is following the same pattern.

Ebola and Dual-Use Research

Dr. Leonard G. Horowitz is an award-winning author, filmmaker, whistleblower, music industry evolutionary and natural medicine pioneer, and author of several books, including ‘Emerging Viruses: AIDs and Ebola – Nature, Accident or Intentional?’.  He is a retired dentist and oral surgeon with a post-doctoral degree in public health.  He currently serves as the editor-in-chief at Medical Veritas, a publication which aims to discover and disclose the truth in health science. 

At the end of last month, he published a 5-page policy review titled ‘Ebola Outbreaks, Dual-Use Research, Reservoir Gaps, and Institutional Conflicts: Critical Analysis of Filovirus Emergence Patterns and Accountability in High-Risk Pathogen Surveillance’ that he had sent to the Centres for Disease Control and Prevention (“CDC”) in Atlanta, USA, for publishing in the medical journal Emerging Infectious Diseases.

It is important to note that dual-use research refers to research that can be used in biodefence as well as in biowarfare (i.e. bioweapons).  Bioweapon research is also called gain-of-function research.

“This manuscript critically examines recurring patterns in filovirus emergence, with particular focus on the 2026 Bundibugyo ebolavirus (BDBV) outbreak, historical lab amplification events, persistent reservoir identification gaps, dual-use research activities (including wildlife pathogen surveillance programmes), and institutional conflicts of interest. It argues for enhanced independent scrutiny, transparency, and governance reforms to better protect public health in an era of advanced reverse genetics and expansive pathogen sampling,” the covering letter to the CDC states.

Dr. Horowitz used the Grok AI program to assist in the synthesis and analysis of his review, which required some corrections of the AI program along the way.  You can read about his method and corrections of the computer program HERE.

The following are some of the highlights from Dr. Horowitz’s review.  You can read the full review HERE.

The Special Virus Cancer Programme and Filovirus Emergence

Filoviruses are a family of single-stranded, negative-sense RNA viruses in the order Mononegavirales, named for their distinctive filamentous or thread-like morphology. The family Filoviridae is currently classified into six genera, two of which are Ebolavirus and Marburgvirus.

Evidence from the US Special Virus Cancer Programme (“SVCP”) demonstrates that early filovirus emergence was primarily driven by laboratory amplification and human-mediated transmission from primate tissues, rather than independent de novo zoonotic spillovers. This was a clear laboratory amplification event and challenges the dominant “natural zoonotic spillover” hypothesis.

The 1967 Marburg outbreak, the first known filovirus outbreak, is a documented example of a laboratory amplification event, where infections occurred in vaccine production laboratories in Germany and Yugoslavia due to the processing of kidney cell cultures and minced tissues from African green monkeys imported from Uganda.

The research involved in the Marburg outbreak was linked to the US Special Virus Cancer Programme, with Litton Bionetics – a subsidiary of major military contractor Litton Industries – playing a central role in primate research and tissue preparation in Northwest Uganda and US facilities.

Studies conducted under the programme involved inoculating rhesus and green monkeys with tumour materials and incubating viruses in tissue cultures.  This raises the problem of disease transmission in humans through vaccines manufactured from non-human primate tissues.

As NIH veterinarian Dr. Robert Whitney stated in 1975 at a Fort Detrick biohazards symposium: “These are viruses which naturally occur in apes and monkeys which are apparently non-pathogenic, but might cause disease in human beings by being transmitted in biologics [vaccines] manufactured from non-human primate [monkey] tissues … Inoculation of the agents by parenteral route is necessary to establish infection in rhesus and cynomolgus monkeys.”

HIV/AIDS Origins and Research Overlaps

The origins of HIV/AIDS have also been linked to dual-use research.

Phylogenetics is the study of the evolutionary history and relationships among organisms or genes, inferred from observable characteristics such as DNA sequences, protein structures and morphology.

Phylogenetic timing overlaps large-scale hepatitis B vaccine trials and the Special Virus Cancer Programme’s primate research, indicating the lab-origins of HIV/AIDS.

However, like with early filovirus emergence, suggestions that vaccine components derived from primate tissues may have contributed to cross-species transmission have faced strong institutional resistance, Dr. Horowitz said.

The 2026 Bundibugyo Ebola Outbreak

The 2026 Bundibugyo ebolavirus (“BDBV”) outbreak in Ituri Province, DRC, follows prior events in 2007 and 2012.  The BDBV genomic sequences cluster with previous lineages.

It is said that BDBV is a zoonotic disease, meaning it spreads from animals to humans, and that fruit bats are suspected to be the natural host.  In other words, the claim is that there has somehow been a zoonotic spillover from bats to humans.

However, the definitive isolation of live BDBV from specific bat colonies matching outbreak strains remains absent, even though extensive bat sampling under USAID’s PREDICT programme (including Metabiota) occurred in the region, Dr. Horowitz pointed out.

[Related: US Company Metabiota Links Biolabs in Africa and Ukraine to the Pentagon’s DTRA]

Additionally, historical records show primate-based research as the dominant early interface. 

So, the lack of isolation of the virus in bats and previous outbreaks being linked to primate-based research raises questions about why the emphasis on bats as the origin of the virus.

“The emphasis on bats as the primary reservoir appears inconsistent with the documented lab-primate transmission history of Marburg and early filovirus awareness. This gap, combined with SVCP-era concealment, weakens confidence in purely natural de novo zoonosis models,” Dr. Horowitz said.

Adding, “US military-industrial programmes (SVCP, Litton Bionetics, Fort Detrick) had strong incentives to minimise public knowledge of lab amplification risks to protect vaccine development and biodefence funding. The promotion of bat reservoir narratives, while partially supported by later ecology, may function in part as a diversion from historical primate research culpability. “

“The historical record from the Special Virus Cancer Programme, Litton Bionetics primate research and Dr. Whitney’s explicit warnings demonstrates that early filoviruses were lab-isolated and transmitted primarily through human activities involving primate tissues, not repeated independent de novo zoonotic spillovers from bats. The persistent emphasis on natural zoonosis despite this evidence is misleading and poses risks to public health and national security,” he concludes.

“Raw genomic data from recent outbreaks must be interpreted in light of this concealed history.  Reservoir gaps, dual-use research overlaps, and institutional conflicts justify equal scrutiny of all hypotheses.”

Source: https://expose-news.com/2026/06/01/previous-outbreaks-of-ebola-were-linked-to/

Fight the Censorship Join the Hopegirl Mailing List and get my free AudioBook: The QEG Chronicles Free Energy Full Disclosure: https://bit.ly/HGQEGBook

HopeGirl Youtube: https://www.youtube.com/@hopegirlblog
HopeGirl Telegram Channel Chat and Groups: https://t.me/Hopegirl587 
Get Our Free EMF Survival Guide : https://bit.ly/FTWEMF
10 Percent Off our EMF Protection Products with this Link: https://www.ftwproject.com/ref/tenoff

The post Previous outbreaks of Ebola were linked to vaccines; the current outbreak should be investigated for the same appeared first on HopeGirl Blog.